Molecular Genetics and Metabolism Reports (Dec 2020)

Clinical outcomes in an adult patient with mannose phosphate isomerase-congenital disorder of glycosylation who discontinued mannose therapy

  • Kinza Noman,
  • Christian J. Hendriksz,
  • Graham Radcliffe,
  • Federico Roncaroli,
  • Sulleman Moreea,
  • Afifah Hussain,
  • Karolina M. Stepien

Journal volume & issue
Vol. 25
p. 100646

Abstract

Read online

The mannose phosphate isomerase-congenital disorder of glycosylation (MPI-CDG) is caused by phosphomannose isomerase deficiency. Clinical features include hyperinsulinaemic hypoglycaemia, protein losing enteropathy, hepatomegaly and hepatic fibrosis, digestive symptoms and coagulation abnormalities. The condition is treated with mannose supplementation. Long-term outcomes in adults are not well described. We present a case of an adult female patient who discontinued mannose therapy in her adolescence. In adulthood she developed gastrointestinal problems, chronic anaemia and osteophytes in her knees.

Keywords